Agentic AI: Altimetrik’s PharmaOS for life sciences
Altimetrik, an AI engineering company, has opened a Healthcare & Life Sciences Center of Excellence (CoE) in Hyderabad, inside its 22,000 sq ft office at Phoenix Equinox in Gachibowli, which houses more than 300 of its employees. The CoE’s first offering is PharmaOS, an agentic AI framework for life sciences built on Altimetrik’s ALTi AIOS platform. The centre will support work across drug discovery, clinical development, commercial operations, manufacturing, patient engagement and care delivery, and Altimetrik says it will build more offerings alongside clients.
PharmaOS brings together more than 35 purpose-built agents and accelerators spanning commercial operations, clinical and regulatory evidence review, manufacturing and quality, responsible AI, and data modernisation. It connects them to enterprise processes and trusted data, traces outputs to source evidence, and keeps people accountable for decisions, according to the company. The framework works with Google, Anthropic and OpenAI ecosystems, with model flexibility from its underlying architecture. Altimetrik says the platform applies to tasks such as clinical study report review, GxP compliance checks and batch-release readiness.
The one-week claim
The headline promise is speed: with a defined business challenge, agreed data access and a bounded workflow, Altimetrik says the CoE can take a client from concept to a “validated, governed AI agentic workflow” in one week. Security, observability, source traceability, quality checks, human decision rights and a measurable business KPI come built in from the outset, so a client can assess the workflow in its own enterprise context before deciding on further investment. Altimetrik chose Hyderabad for its pharmaceutical and contract-research base and its pool of clinical, regulatory and quality specialists.
The GxP reality
The word doing the heavy lifting is “validated,” and in life sciences that word has a specific, regulated meaning. In January 2026 the FDA and EMA published joint guidance on good AI practice in drug development, stressing a risk-based approach, adherence to GxP, data governance and life-cycle management. Gartner’s March 2026 guidance told life-science CIOs they must reimagine GxP validation for AI and agentic systems. The draft EU GMP Annex 22 is more restrictive still: it excludes generative AI and large language models from critical GMP applications and permits them in non-critical ones only with a human in the loop.
Independent analysis of how to validate a non-deterministic agent — one whose output changes between runs — is blunt about the effort involv. A commonly cited practitioner framework argues teams should qualify such an agent like an analytical method rather than like software: a narrowly bounded context of use, acceptance criteria set on a distribution rather than a single output, a pinned and change-controlled model version, continued verification after go-live, and a named, qualified human reviewer. That is a multi-month discipline. Altimetrik’s one-week model, by contrast, is explicitly bounded — a defined challenge, agreed data, a bounded workflow — and produces a working workflow with governance built in. Read plainly, that is a governed proof of concept, not the validated production system the word implies.
What to watch
Three things will show whether the CoE matters. First, whether Altimetrik names a client that completed the one-week model, since it has disclosed no customer and no one has independently verified performance. Second, whether it publishes the validation evidence its GxP language implies, because regulated buyers will ask for it. Third, whether the model-flexibility pitch survives contact with Annex 22-style restrictions on generative AI in critical GMP work, which could narrow where these agents operate.
What the launch does and doesn’t establish
It establishes a new CoE, a 35-plus-agent framework for life sciences, a one-week bounded engagement model, and support for major model providers. It does not establish any client outcome, independent validation of the agents, or that a one-week workflow meets the qualification standard a regulated life-sciences system requires.
The honest summary: this is a sensible product aim at a real problem — how to put agentic AI into regulated life-sciences workflows without losing the evidence trail — and the emphasis on traceability and human decision rights fits where the industry is heading. The caution is the word “validated.” GxP validation of non-deterministic agents is a serious, having evidence, multi-stage exercise, and a one-week engagement, however well governing, is best as a proof of concept. The framework may well be a good starting point; the marketing should not mistake for a qualification.
Editor’s Note: This article about PharmaOS draws on the Altimetrik release and the company’s published materials, plus independent coverage by The Hindu, The Hindu BusinessLine, the Times of India and Tech Observer, and independent guidance by the FDA and EMA, Gartner, and ISPE/GAMP-aligned research on GxP validation of AI. The framework’s features are as per Altimetrik’s description. There’s no disclosure of customer or validation data. he “validated in a week” claim is a company description.